Valerio Costa
Overview
Explore the profile of Valerio Costa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ambrosio M, Adriaens M, Derks K, Migliaccio T, Costa V, Liguoro D, et al.
Sci Rep
. 2024 Oct;
14(1):24674.
PMID: 39433816
An established hallmark of cancer cells is metabolic reprogramming, largely consisting in the exacerbated glucose uptake. Adipocytes in the tumor microenvironment contribute toward breast cancer (BC) progression and are highly...
2.
Costa V, Giovannetti E, Lonardo E
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201558
This Special Issue includes original articles and reviews on both established and innovative approaches to cancer targeting, showcased at the 29th IGB Workshop titled "Targeting the (un)usual suspects in cancer"...
3.
Aprile M, Cataldi S, Perfetto C, Federico A, Ciccodicola A, Costa V
Br J Cancer
. 2023 May;
129(2):249-265.
PMID: 37198319
Background: B-raf inhibitors (BRAFi) are effective for BRAF-mutated papillary (PTC) and anaplastic (ATC) thyroid carcinomas, although acquired resistance impairs tumour cells' sensitivity and/or limits drug efficacy. Targeting metabolic vulnerabilities is...
4.
Cataldi S, Aprile M, Perfetto C, Angot B, Cormont M, Ciccodicola A, et al.
Eur J Cell Biol
. 2023 May;
102(2):151320.
PMID: 37130450
Adipose tissue (AT) dysfunctions are associated with the onset of insulin resistance (IR) and type 2 diabetes mellitus (T2DM). Targeting glucose-dependent insulinotropic peptide receptor (GIPR) is a valid option to...
5.
Fasciolo G, Napolitano G, Aprile M, Cataldi S, Costa V, Muscari Tomajoli M, et al.
Antioxidants (Basel)
. 2023 Mar;
12(3).
PMID: 36978840
While a low level of ROS plays a role in cellular regulatory processes, a high level can lead to oxidative stress and cellular dysfunction. Insulin resistance (IR) is one of...
6.
Cataldi S, Tramontano M, Costa V, Aprile M, Ciccodicola A
Antioxidants (Basel)
. 2022 Oct;
11(10).
PMID: 36290744
The growing incidence of diabetes mellitus worldwide implies the increasing prevalence of several related macro- (e.g., hypertension and atherosclerosis) and micro-vascular (e.g., nephropathy and retinopathy) complications. Notably, diabetic retinopathy (DR)...
7.
Drongitis D, Verrillo L, De Marinis P, Orabona P, Caiola A, Turitto G, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142158
Glioblastoma multiforme (GBM) is a fatal brain tumor without effective drug treatment. In this study, we highlight, for the first time, the contribution of chromatin remodeling gene Lysine (K)-specific demethylase...
8.
Aprile M, Costa V, Cimmino A, Calin G
Int J Cancer
. 2022 Sep;
152(5):822-834.
PMID: 36082440
The view of long noncoding RNAs as nonfunctional "garbage" has been definitely outdated by the large body of evidence indicating this class of ncRNAs as "golden junk", especially in precision...
9.
Fasciolo G, Napolitano G, Aprile M, Cataldi S, Costa V, Ciccodicola A, et al.
Antioxidants (Basel)
. 2022 Jul;
11(7).
PMID: 35883786
Thyroid hormones are normally involved in glycaemic control, but their excess can lead to altered glucose metabolism and insulin resistance (IR). Since hyperthyroidism-linked increase in ROS results in tissue oxidative...
10.
Federico A, Fratello M, Scala G, Mobus L, Pavel A, Del Giudice G, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454948
Despite remarkable efforts of computational and predictive pharmacology to improve therapeutic strategies for complex diseases, only in a few cases have the predictions been eventually employed in the clinics. One...